Keywords: first, approval, delavirdine, nnrti, pharmacia, upjohn, rescriptor
First Approval For Delavirdine NNRTI
Article | 07 April 1997
Pharmacia & Upjohn's Rescriptor (delavirdine) has been approved in itsfirst market, the USA, and becomes the second non-nucleoside reverse transcriptase inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
